The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Systematic review and meta-analysis of PD-1 and PD-L1 inhibitors in triple-negative breast cancer: A focus on survival, metastasis, and recurrence.
 
Milton Trujillo Asturias
No Relationships to Disclose
 
Jose Flores Valdes
No Relationships to Disclose
 
Rafael Pinto-Colmenarez
No Relationships to Disclose
 
Omar Borges-Sosa
No Relationships to Disclose
 
Jaqueline Livier Castillo
No Relationships to Disclose
 
Marian Iniesta Vallejo
No Relationships to Disclose
 
Angel Ayala
No Relationships to Disclose
 
Mauricio Montelongo-Quevedo
No Relationships to Disclose
 
Nitzia Quilantan
No Relationships to Disclose
 
Ana Maria Mendoza Sanchez
No Relationships to Disclose
 
Julieta Arguelles-Hernandez
No Relationships to Disclose
 
Luis Norzagaray Figueroa
No Relationships to Disclose
 
Jennifer Castillo
No Relationships to Disclose
 
Julio Peguero
Employment - Oncology Consultants
Leadership - Oncology Consultants
Stock and Other Ownership Interests - Consultores en Oncologia; Oncology Consultants; zogen
Consulting or Advisory Role - Exigent Research Network
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BerGenBio (Inst); Dizal Pharma (Inst); eFFECTOR Therapeutics (Inst); Epizyme (Inst); Genentech/Roche (Inst); ImmunityBio (Inst); Immutep (Inst); Incyte (Inst); Ipsen (Inst); Janssen (Inst); Kechow Pharma (Inst); Lilly (Inst); Macrogenics (Inst); Mirati Therapeutics (Inst); Natera (Inst); Novartis (Inst); OncoC4 (Inst); QSAM (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Systimmune (Inst)